Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.

Recruiting now

Conditions studied: Chronic Inflammatory Demyelinating Polyneuropathy

In brief

ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis. The investigators plan to include a group of approximately 40 patients with CIDP. The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.

Key facts

Study ID

NCT06183645

Run by

Centre Hospitalier Universitaire de Liege

People needed

40

Starts

2023-08-28

Expected to finish

2028-01-01

Last updated by the study team

2025-02-12

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2.
• Treated with IVIg (≤1g/kg/3-8week)
• Clinically Stable disease for 3 months (according to treating physician opinion).
• No treatment withdrawal failure within 1 year
• Age over 18 years

You may not qualify if…

• Significant cognitive or communication disorders
• Surgery or serious traumatic injury ≤ 6 months
• Non ambulant patient
• Current participation to a therapeutic trial
• Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy
• Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment
• Pregnancy or breastfeeding
• Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.

Where it is running

• CHR Citadelle — Liège, Liège, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.